Idorsia insomnia drug starts FDA review as founder Clozel's second act proceeds

ZURICH (Reuters) - Idorsia’s insomnia drug was accepted for review by U.S. regulators, the Swiss drugmaker said on Wednesday, as founder Jean-Paul Clozel edges closer to bringing his new company’s first drug to market since selling Actelion for $30 billion. The U.S. Food and Drug Administration agreed to consider the medicine daridorexant for approval, as Idorsia seeks to go up against a similar drug, Merck’s Belsomra, which last year racked up $327 million in sales.
Read more...

;